Skip to content

Scale Down for Endometrial Cancer

Scale Down: A Randomized, Controlled Weight Management Intervention for Women With Endometrial Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03169023
Enrollment
155
Registered
2017-05-30
Start date
2017-02-21
Completion date
2019-02-03
Last updated
2019-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of the Endometrium, Endometrial Cancer

Brief summary

This proposal will pilot a weight management program for patients with endometrial cancer, the cancer most associated with obesity. If successful, this pilot could be expanded to include obese women with other gynecologic cancers (ovarian and cervical) and could be expanded and adapted for use not only upon completion of treatment, but during chemotherapy or radiation. Furthermore, other obstetricians and gynecologists could use this strategy for obese women as a practical cancer prevention strategy for obesity-associated cancers.

Interventions

BEHAVIORALScaleDown

-Participants receives behavioral prompts and daily feedback by text messaging with motivational instructions for specific dietary and behavior modifications

BEHAVIORALEnhanced Usual Care Packets

-From the American Cancer Society Website

OTHER12-Item Short Form Health Survey

-Measures functional health and well-being from the patient's perspective

OTHERInternational Physical Activity Questionnaire short form

-7 item scale that measures a range of physical activity from vigorous to sedentary over the last 7 days

OTHERMultidimensional Body Self Relations Questionnaire - Appearance Subscales

-Gold-standard for the assessment of body image attitudes and contains 34 items

OTHERCancer-Related Body Image Scale

-13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment

OTHERPatient Health Questionnaire 9-Item Version

-Widely used measure that assesses mood, including an item that screens for suicidality

BEHAVIORALiOTA

-Washington University based intervention

Sponsors

ScaleDown
CollaboratorUNKNOWN
Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female women 18 years of age or older and with biopsy-proven endometrial cancer. * BMI greater than or equal to 30 kg/m\^2. * Must be able to read and speak English. * All patients must be informed of the investigational nature of this study and must sign and give written informed consent for Aim 1 study activities in accordance with institutional and federal guidelines. * Has completed prior surgical management and adjuvant endometrial cancer treatment, if adjuvant treatment is indicated, prior to starting Aim 1. * Is not receiving concurrent cytotoxic chemotherapy and/or radiation therapy at time of enrollment AND, if randomized, is not anticipated that the participant will need to receive concurrent cytotoxic chemotherapy and/or radiation therapy at any time during the Aim 1 intervention * Patients with BMI greater than or equal to 30 kg/m\^2 who are undergoing hormonal treatment of endometrial cancer. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Life expectancy of at least one year * Must have a phone capable of receiving text messages.

Exclusion criteria

* Females under the age of 18 years * BMI less than 30 kg/m\^2 * Must not be participating in another formal weight loss program. * Must not have any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a participant's ability to give informed consent. * For participants who are randomized in Aim 1: * No uncontrolled serious medical or psychiatric condition(s) that would affect the patient's ability to participate in the interventional study, e.g., uncontrolled hypertension, symptomatic cardiac disease, or severe/uncontrolled depression as indicated by a previously completed Patient Health Questionnaire (PHQ-9) score \>9 (Kroenke) * No diagnoses of any other invasive malignancy other than endometrial cancer or non-melanoma skin cancer which required active treatment currently or within the last 2 years.

Design outcomes

Primary

MeasureTime frameDescription
Mean weight loss compared between the two armsUp to 12 months-The purpose will be to obtain estimates for the size of an effect achievable by the experimental intervention in order to power and justify a full-scale trial of a weight management program in women with endometrial cancer.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026